These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 37531032)

  • 41. The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.
    van Hoogstraten WS; MaassenVanDenBrink A
    J Headache Pain; 2019 May; 20(1):54. PubMed ID: 31096904
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.
    Dubowchik GM; Conway CM; Xin AW
    J Med Chem; 2020 Jul; 63(13):6600-6623. PubMed ID: 32058712
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluating rimegepant for the treatment of migraine.
    de Vries T; Al-Hassany L; MaassenVanDenBrink A
    Expert Opin Pharmacother; 2021 Jun; 22(8):973-979. PubMed ID: 33648385
    [No Abstract]   [Full Text] [Related]  

  • 44. Rimegepant: acute treatment for migraine headaches.
    Peters GL; Hennessey EK
    Pain Manag; 2021 May; 11(3):259-266. PubMed ID: 33550872
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.
    Polavieja P; Belger M; Venkata SK; Wilhelm S; Johansson E
    J Headache Pain; 2022 Jul; 23(1):76. PubMed ID: 35790906
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Migraine therapeutics differentially modulate the CGRP pathway.
    Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
    Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.
    Goadsby PJ; Tepper SJ; Watkins PB; Ayele G; Miceli R; Butler M; Severt L; Finnegan M; Szegedi A; Trugman JM; Jakate A
    Cephalalgia; 2019 Dec; 39(14):1753-1761. PubMed ID: 31537107
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Atogepant (Qulipta) for migraine prevention.
    Med Lett Drugs Ther; 2021 Nov; 63(1636):169-171. PubMed ID: 35085204
    [No Abstract]   [Full Text] [Related]  

  • 50. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants.
    Do TP; Al-Saoudi A; Ashina M
    Rev Neurol (Paris); 2021 Sep; 177(7):827-833. PubMed ID: 34294458
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk.
    Mathew PG; Klein BC
    Headache; 2019 Sep; 59(8):1421-1426. PubMed ID: 31318457
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gepants in the acute management of migraine.
    Wells-Gatnik WD; Martelletti P
    Pain Manag; 2023 Nov; 13(11):627-630. PubMed ID: 37942638
    [No Abstract]   [Full Text] [Related]  

  • 53. New Generation Gepants: Migraine Acute and Preventive Medications.
    Moreno-Ajona D; Villar-Martínez MD; Goadsby PJ
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329982
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis.
    Ha DK; Kim MJ; Han N; Kwak JH; Baek IH
    Clin Drug Investig; 2021 Feb; 41(2):119-132. PubMed ID: 33426614
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
    Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
    Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Calcitonin Gene-Related Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta-Analysis.
    Chan TLH; Cowan RP; Woldeamanuel YW
    Headache; 2020 Jul; 60(7):1489-1499. PubMed ID: 32515018
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries.
    Rubio-Beltran E; Chan KY; Danser AJ; MaassenVanDenBrink A; Edvinsson L
    Cephalalgia; 2020 Apr; 40(4):357-366. PubMed ID: 31674221
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Atogepant: Mechanism of action, clinical and translational science.
    Boinpally R; Shebley M; Trugman JM
    Clin Transl Sci; 2024 Jan; 17(1):e13707. PubMed ID: 38266063
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent Advances in Pharmacotherapy for Episodic Migraine.
    Chan C; Goadsby PJ
    CNS Drugs; 2019 Nov; 33(11):1053-1071. PubMed ID: 31556018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.